M Pharmaceutical Inc. (CSE:MQ) announced that Dr. Martin Mintchev, PhD, has resigned from the board of directors of M Pharmaceutical Inc. and from his position as chief scientific officer with immediate effect.
M Pharma recently announced it had entered into a letter of intent to acquire reformulated orlistat from Chelatexx LLC (C-103) and a significant reorganization of its priorities to concentrate on the development of oral products for obesity treatment and weight loss. The management of M Pharma and Chelatexx LLC are currently reviewing the proposed acquisition structure for tax efficiency.
M Pharmaceutical CEO, Matthew Lehman, stated:

On behalf of the M Pharma board of directors, we thank Dr. Mintchev for his service to help start the company. His creative insights are the driving factor behind much of M Pharma’s innovative technology. We wish him well with his teaching and research endeavours.

Connect with M Pharmaceutical Inc. (CSE:MQ) to receive an Investor Kit

acquisition board of directors m pharmaceutical inc.martin mintchev weight loss Company News